The treatment-resistant depression treatment market is projected to grow from USD 2.0 billion in 2025 to USD 4.8 billion by 2035, at a CAGR of 9.0%. NMDA will dominate with a 48.3% market share, while hospital pharmacies will lead the distribution channel segment with a 46.7% share.